keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis cardiovascular event

keyword
https://www.readbyqxmd.com/read/29782642/tofacitinib-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis-long-term-safety-and-efficacy-in-an-open-label-extension-study
#1
F Valenzuela, N J Korman, R Bissonnette, N Bakos, T-F Tsai, M K Harper, W C Ports, H Tan, A Tallman, H Valdez, A C Gardner
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported. OBJECTIVE: To evaluate the long-term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis. METHODS: Eligible patients who completed qualifying Phase 2/3 tofacitinib studies received tofacitinib 10 mg twice daily (BID) until Month 3; subsequently, the dose could be adjusted by investigators to either 5 or 10 mg BID...
May 21, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29776990/effect-of-2-psoriasis-treatments-on-vascular-inflammation-and-novel-inflammatory-cardiovascular-biomarkers-a-randomized-placebo-controlled-trial
#2
Nehal N Mehta, Daniel B Shin, Aditya A Joshi, Amit K Dey, April W Armstrong, Kristina Callis Duffin, Zelma Chiesa Fuxench, Charlotte L Harrington, Rebecca A Hubbard, Robert E Kalb, Alan Menter, Daniel J Rader, Muredach P Reilly, Eric L Simpson, Junko Takeshita, Drew A Torigian, Thomas J Werner, Andrea B Troxel, Stephen K Tyring, Suzette Baez Vanderbeek, Abby S Van Voorhees, Martin P Playford, Mark A Ahlman, Abass Alavi, Joel M Gelfand
BACKGROUND: Psoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality. We aimed to assess and compare the effect of treatment of moderate-to-severe psoriasis with adalimumab or phototherapy on vascular inflammation and cardiovascular biomarkers. METHODS AND RESULTS: Randomized, double-blind, trial of adalimumab, phototherapy, and placebo (1:1:1) for 12 weeks, with crossover to adalimumab for 52 weeks total. Outcomes included vascular inflammation by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography and biomarkers of inflammation, insulin resistance, and lipoproteins...
June 2018: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29742274/safety-of-tildrakizumab-for-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-three-randomised-controlled-trials
#3
A Blauvelt, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz, S Green, C La Rosa
BACKGROUND: Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated. OBJECTIVES: Safety/tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from 3 randomised controlled trials for moderate-to-severe psoriasis. METHODS: Data pools for the placebo-controlled (up to 16 weeks) and full-trial periods (up to 64 weeks) were analysed (N=2081). RESULTS: In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range=47...
May 9, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29683293/psoriasis-as-a-cardiovascular-risk-factor-updates-and-algorithmic-approach
#4
Emanuele Cozzani, Gianmarco Rosa, Martina Burlando, Aurora Parodi
Although psoriasis is predominantly a chronic inflammatory skin disorder, it has been known to be associated with cardiovascular disease. Patients with psoriasis, particularly with moderate to severe forms, present an increased rate of cardiovascular mortality, myocardial infarction and stroke. However the pathophysiology of the relationship between psoriasis and cardiovascular risk and comorbidities has not yet completely known. Chronic inflammation may be considered a solid link between psoriasis and related cardiovascular events...
April 19, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29662733/psoriasis-and-cardiovascular-diseases-a-literature-review-to-determine-the-causal-relationship
#5
REVIEW
Shanu Jindal, Nitin Jindal
Psoriasis is a chronic, complex autoimmune disease characterized by erythematous, scaly patches over extensor aspects of skin and is associated with joint involvement in about one-third of patients. An association between psoriasis and cardiovascular diseases (CVD) has been a topic of dilemma, and many studies have shown an increased risk of cardiovascular morbidity in patients with psoriasis. There is increasing evidence that psoriasis is associated with higher risk of CVD and increased prevalence of cardiovascular risk factors, as compared with the general population...
February 15, 2018: Curēus
https://www.readbyqxmd.com/read/29656791/cardiovascular-risk-factors-predicting-cardiac-events-are-different-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis
#6
Roxanne Cooksey, Sinead Brophy, Jonathan Kennedy, Fabiola Fernandez Gutierrez, Tim Pickles, Ruth Davies, Vincent Piguet, Ernest Choy
OBJECTIVES: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in psoriatic arthritis (PsA) and RA...
March 17, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29653208/efficacy-and-safety-of-ixekizumab-over-4-years-of-open-label-treatment-in-a-phase-2-study-in-chronic-plaque-psoriasis
#7
Claus Zachariae, Kenneth Gordon, Alexandra Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, Gregory Cameron
BACKGROUND: Ixekizumab has demonstrated improvement in moderate-to-severe psoriasis patients by selectively targeting interleukin-17A, a pro-inflammatory cytokine important in psoriasis pathogenesis. OBJECTIVE: To report 4-year efficacy and safety results from the open-label extension (OLE) of this phase 2 trial. METHODS: Analysis was by last observation carried forward. Patients received ixekizumab 120 mg then 80 mg subcutaneously once every 4 weeks...
April 10, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29625133/does-biologic-treatment-of-psoriasis-lower-the-risk-of-cardiovascular-events-and-mortality-a-critical-question-that-we-are-only-just-beginning-to-answer
#8
Joel M Gelfand
No abstract text is available yet for this article.
April 3, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29573294/anti-inflammatory-therapy-with-tumor-necrosis-factor-inhibitors-is-associated-with-reduced-risk-of-major-adverse-cardiovascular-events-in-psoriasis
#9
Jashin J Wu, Aditya A Joshi, Shivani P Reddy, Michael Batech, Alexander Egeberg, Ole Ahlehoff, Nehal N Mehta
BACKGROUND: Psoriasis is a systemic chronic inflammatory condition associated with increased risk of cardiovascular disease. Data demonstrating that decreased skin inflammation reduces cardiovascular events in psoriasis patients may be generalizable to other chronic inflammatory states with heightened cardiovascular risk. OBJECTIVE: To determine whether tumor necrosis factor inhibitor (TNFi) therapy is associated with decreased major adverse cardiovascular events (MACE) in psoriasis patients...
March 24, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29559399/ustekinumab-treatment-is-associated-with-decreased-systemic-and-vascular-inflammation-in-patients-with-moderate-to-severe-psoriasis-feasibility-study-using-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#10
Byung-Soo Kim, Won-Ku Lee, Kyoungjune Pak, Junhee Han, Gun-Wook Kim, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Seong-Jang Kim
BACKGROUND: Evidence suggests that psoriasis may be associated with metabolic syndrome and an increased risk of cardiovascular disease. OBJECTIVE: To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT). METHODS: Patients with psoriasis and healthy controls underwent baseline 18 F-FDG PET/CT imaging...
March 17, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29557200/new-therapies-versus-first-generation-biologic-drugs-in-psoriasis-a-review-of-adverse-events-and-their-management
#11
J M Carrascosa, E Del-Alcazar
Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the main adverse events associated with the biologic agents currently available for the treatment of psoriasis and the new inhibitors targeting the p19 subunit of interleukin (IL) 23 and the IL-17A receptor. This review covers injection site reactions, infections, cardiovascular events, demyelinating disorders, tumours, class effects secondary adverse events, immunogenicity, safety in pregnancy and vaccines efficacy...
March 20, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29542417/cardiovascular-risk-markers-and-major-adverse-cardiovascular-events-in-psoriatic-arthritis-patients
#12
Rosario Peluso, Francesco Caso, Marco Tasso, Pasquale Ambrosino, Matteo Nicola, Dario Di Minno, Roberta Lupoli, Livio Criscuolo, Paolo Caso, Francesco Ursini, Antonio Del Puente, Raffaele Scarpa, Luisa Costa
BACKGROUND: Psoriatic arthritis is a chronic inflammatory arthropathy that affects 14%-30% of patients with skin and/or nail psoriasis and leading to severe physical limitations and disability. It has been included in the group of spondyloarthropathy with which it shares clinical, radiologic, and serologic features in addition to familial and genetic relationship. Beyond skin and joint involvement, psoriatic arthritis is characterized by a high prevalence of extra-articular manifestation and comorbidities, such as autoimmune, infectious and neoplastic diseases...
March 13, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29535705/immune-mediated-inflammation-promotes-subclinical-atherosclerosis-in-recent-onset-psoriatic-arthritis-patients-without-conventional-cardiovascular-risk-factors
#13
Rodolfo A Kolliker Frers, Vanesa Cosentino, Julia Tau, Eduardo M Kerzberg, Adriana Urdapilleta, Monica Chiocconi, Nora Kogan, Matilde Otero-Losada, Francisco Capani
Studies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients without conventional cardiovascular risk factors (CVRFs) are not available. This preliminary study focuses on cardiovascular risk in cutaneous psoriasis (CPs) and recent-onset PsA patients. Blood biochemistry (glucose, cholesterol, uric acid, lipid profile and apolipoprotein B) was analyzed using standard kits. Proatherogenic inflammation markers, C-reactive protein (CRP) and interleukin-6 (IL-6), and endothelial activators monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1), were determined by enzyme-linked immunosorbent assay...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29499292/the-risk-of-cardiovascular-events-in-psoriasis-patients-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-versus-phototherapy-an-observational-cohort-study
#14
Jashin J Wu, Murali Sundaram, Martin Cloutier, Marjolaine Gauthier-Loiselle, Annie Guérin, Rakesh Singh, Arijit Ganguli
BACKGROUND: Psoriasis is a risk factor for cardiovascular events. OBJECTIVE: To assess the risk of major cardiovascular events and the effect of cumulative treatment exposure on cardiovascular event risk in patients with psoriasis treated with tumor necrosis factor-α inhibitors (TNFis) versus phototherapy. METHODS: Adult patients with psoriasis were selected from a large US administrative claims database (from the first quarter of 2000 through the third quarter of 2014) and classified in 2 mutually exclusive cohorts based on whether they were treated with TNFis or phototherapy...
March 1, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29470738/prevalence-and-type-ii-diabetes-associated-factors-in-psoriatic-arthritis
#15
Rubén Queiro, Andrés Lorenzo, Estefanía Pardo, Anahy Brandy, Pablo Coto, Javier Ballina
Diabetes is a common cardiovascular risk factor in psoriatic arthritis (PsA). Although the prevalence of diabetes is high, the factors associated with it in PsA are poorly understood. We aimed to analyse the prevalence of type II diabetes and diabetes-associated factors in a hospital-based population with PsA. This cross-sectional study included 340 consecutive patients attended in a tertiary care hospital. The prevalence of diabetes was compared to that of 600 outpatients without inflammatory conditions. To analyse diabetes-associated factors, odds ratio (OR) values were calculated by conditional logistic regression analysis...
April 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29404966/efficacy-and-safety-of-secukinumab-in-elderly-subjects-with-moderate-to-severe-plaque-psoriasis-a-pooled-analysis-of-phase-iii-studies
#16
Andreas Körber, Charis Papavassilis, Vaishali Bhosekar, Maximilian Reinhardt
BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting patients of a wide age range, including elderly patients. Elderly patients can respond differently to drug treatments and can be more vulnerable to adverse reactions. There are limited data on biologic therapies for psoriasis in elderly subjects. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has proven significant efficacy in the treatment of moderate to severe psoriasis. AIMS: A post-hoc analysis of three phase III trials (ERASURE, FIXTURE and CLEAR) was performed to evaluate the efficacy and safety of secukinumab in elderly subjects...
February 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29305563/arterial-stiffness-association-with-chronic-inflammatory-disorders-in-the-uk-biobank-study
#17
Alex Dregan
OBJECTIVE: The present study tested the hypothesis that arterial stiffness will be elevated across overall and specific inflammatory disorders compared with an inflammation-free comparison group. METHODS: Adults (n=171 125) aged 40-70 years from the UK Biobank who were cardiovascular disease (CVD) free and who had their arterial stiffness assessed at the time of study recruitment between 2006 and 2010 were included. The main exposure was represented by a global measure of chronic inflammatory disorders...
January 4, 2018: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/29149819/cardiovascular-risk-in-psoriasis-current-state-of-the-art
#18
Giuseppe Dattilo, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinella Cannavo
Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of psoriatic arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients...
November 16, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29145701/editorial-tumor-necrosis-factor-antagonists-killing-two-birds-with-one-biologic-stone
#19
EDITORIAL
Joan M Bathon, Jon T Giles, Daniel H Solomon
No abstract text is available yet for this article.
March 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29094341/safety-efficacy-and-drug-survival-of-biologics-and-biosimilars-for-moderate-to-severe-plaque-psoriasis
#20
A Egeberg, M B Ottosen, R Gniadecki, S Broesby-Olsen, T N Dam, L E Bryld, M K Rasmussen, L Skov
BACKGROUND: Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics...
February 2018: British Journal of Dermatology
keyword
keyword
114302
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"